- Home
- KPTI vs ADAG Comparison
KPTI vs ADAG Comparison
Compare KPTI & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- ADAG
- Stock Information
- Founded
- KPTI 2008
- ADAG 2011
- Country
- KPTI United States
- ADAG China
- Employees
- KPTI 325
- ADAG N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- KPTI Health Care
- ADAG Health Care
- Exchange
- KPTI Nasdaq
- ADAG Nasdaq
- Market Cap
- KPTI 105.9M
- ADAG 98.3M
- IPO Year
- KPTI 2013
- ADAG 2021
- Fundamental
- Price
- KPTI $0.85
- ADAG $2.19
- Analyst Decision
- KPTI Strong Buy
- ADAG Strong Buy
- Analyst Count
- KPTI 4
- ADAG 1
- Target Price
- KPTI $5.00
- ADAG $5.00
- AVG Volume (30 Days)
- KPTI 1.1M
- ADAG 59.4K
- Earning Date
- KPTI 11-05-2024
- ADAG 07-25-2024
- Dividend Yield
- KPTI N/A
- ADAG N/A
- EPS Growth
- KPTI N/A
- ADAG N/A
- EPS
- KPTI N/A
- ADAG N/A
- Revenue
- KPTI $148,442,000.00
- ADAG $815,746.00
- Revenue This Year
- KPTI $6.67
- ADAG N/A
- Revenue Next Year
- KPTI $8.58
- ADAG $2.70
- P/E Ratio
- KPTI N/A
- ADAG N/A
- Revenue Growth
- KPTI 1.77
- ADAG N/A
- 52 Week Low
- KPTI $0.62
- ADAG $1.35
- 52 Week High
- KPTI $1.95
- ADAG $4.38
- Technical
- Relative Strength Index (RSI)
- KPTI 50.60
- ADAG 38.91
- Support Level
- KPTI $0.75
- ADAG $2.09
- Resistance Level
- KPTI $0.95
- ADAG $2.37
- Average True Range (ATR)
- KPTI 0.07
- ADAG 0.30
- MACD
- KPTI -0.01
- ADAG -0.07
- Stochastic Oscillator
- KPTI 46.97
- ADAG 16.10
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.